| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778393 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
| US9320710 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
| US8535714 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
| US8778394 | ACELRX PHARMS | Small-volume oral transmucosal dosage forms |
Jan, 2027
(3 years from now) | |
| US10342762 | ACELRX PHARMS | Small-volume oral transmucosal dosage forms |
Jan, 2027
(3 years from now) | |
| US8231900 | ACELRX PHARMS | Small-volume oral transmucosal dosage |
Jan, 2027
(3 years from now) | |
| US8252328 | ACELRX PHARMS | Bioadhesive drug formulations for oral transmucosal delivery |
Jan, 2027
(3 years from now) | |
| US9744129 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
| US8252329 | ACELRX PHARMS | Bioadhesive drug formulations for oral transmucosal delivery |
Jan, 2027
(3 years from now) | |
| US8226978 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
| US8865211 | ACELRX PHARMS | Bioadhesive drug formulations for oral transmucosal delivery |
Jan, 2027
(3 years from now) | |
| US10245228 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
| US10507180 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
| US10896751 | ACELRX PHARMS | Storage and dispensing devices for administration of oral transmucosal dosage forms |
Mar, 2030
(6 years from now) | |
| US8574189 | ACELRX PHARMS | Storage and dispensing devices for administration of oral transmucosal dosage forms |
Mar, 2030
(6 years from now) | |
| US8865743 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Oct, 2030
(7 years from now) | |
| US8202535 | ACELRX PHARMS | Small-volume oral transmucosal dosage forms |
Oct, 2030
(7 years from now) | |
| US8945592 | ACELRX PHARMS | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
Jul, 2031
(7 years from now) | |
Dsuvia is owned by Acelrx Pharms.
Dsuvia contains Sufentanil Citrate.
Dsuvia has a total of 18 drug patents out of which 0 drug patents have expired.
Dsuvia was authorised for market use on 02 November, 2018.
Dsuvia is available in tablet;sublingual dosage forms.
Dsuvia can be used as treatment of acute pain.
The generics of Dsuvia are possible to be released after 29 July, 2031.
Drugs and Companies using SUFENTANIL CITRATE ingredient
Market Authorisation Date: 02 November, 2018
Treatment: Treatment of acute pain
Dosage: TABLET;SUBLINGUAL
DSUVIA family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11676691 | VERTICAL PHARMS | Storage and dispensing devices for administration of oral transmucosal dosage forms |
Mar, 2030
(6 years from now) | |
| US11672738 | VERTICAL PHARMS | Apparatus and methods for dispensing oral transmucosal dosage forms |
Feb, 2038
(14 years from now) | |
Dsuvia is owned by Vertical Pharms.
Dsuvia contains Sufentanil Citrate.
Dsuvia has a total of 2 drug patents out of which 0 drug patents have expired.
Dsuvia was authorised for market use on 02 November, 2018.
Dsuvia is available in tablet;sublingual dosage forms.
The generics of Dsuvia are possible to be released after 02 February, 2038.
Drugs and Companies using SUFENTANIL CITRATE ingredient
Market Authorisation Date: 02 November, 2018
Treatment: NA
Dosage: TABLET;SUBLINGUAL
DSUVIA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic